The influence of androgen deprivation therapy on hip geometric properties and bone mineral density in Japanese men with prostate cancer and its relationship with the visceral fat accumulation

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25(6):524–531.
   PubMed Web of Science ®Google Scholar
• Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, et al. The incidence and mortality of prostate cancer and its relationship with development in Asia. Prostate Int. 2015;3(4):135–140.
   PubMed Web of Science ®Google Scholar
• Ceylan Y, Gunlusoy B, Koskderelioglu A, et al. The depressive effects of androgen deprivation therapy in locally advanced or metastatic prostate cancer: a comparative study. Aging Male. [cited 2019 Mar 29]; [7 p.]. DOI:10.1080/13685538.2019.1586869
   Web of Science ®Google Scholar
• Chen YZ, Chiang PK, Lin WR, et al. The relationship between androgen deprivation therapy and depression symptoms in patients with prostate cancer. Aging Male. [cited 2019 Jan 16]; [6 p.]. DOI:10.1080/13685538.2018.1560404
   Web of Science ®Google Scholar
• Wong SK, Mohamad NV, Jayusman PA, et al. The use of selective estrogen receptor modulators on bone health in men. Aging Male. 2019;22(2):89–101.
   PubMed Web of Science ®Google Scholar
• Ryu JH, Kim SJ, Kim YB, et al. Radical prostatectomy for clinically localized prostate cancer in patients aged 75 years or older: comparison with primary androgen deprivation therapy. Aging Male. 2018;21(1):17–23.
   PubMed Web of Science ®Google Scholar
• Jhan JH, Yang YH, Chang YH, et al. Hormone therapy for prostate cancer increases the risk of Alzheimer’s disease: a nationwide 4-year longitudinal cohort study. Aging Male. 2017;20(1):33–38.
   PubMed Web of Science ®Google Scholar
• Urushima H, Inomata-Kurashiki Y, Nishimura K, et al. The effects of androgen deprivation therapy with weight management on serum aP2 and adiponectin levels in prostate cancer patients. Aging Male. 2015;18(2):72–76.
   PubMed Web of Science ®Google Scholar
• Wright-St Clair VA, Malcolm W, Keogh JW. The lived experience of physically active older prostate cancer survivors on androgen deprivation therapy. Aging Male. 2014;17(1):57–62.
   PubMed Web of Science ®Google Scholar
• Haidar A, Yassin A, Saad F, et al. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male. 2007;10(4):189–196.
   PubMed Web of Science ®Google Scholar
• Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Rev Urol. 2008;5(1):24–34.
   Web of Science ®Google Scholar
• Morote J, Morin JP, Orsola A, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69(3):500–504.
   PubMed Web of Science ®Google Scholar
• Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–164.
   PubMed Web of Science ®Google Scholar
• Van Hemelrijck M, Garmo H, Michaelsson K, et al. Mortality following hip fracture in men with prostate cancer. PLoS One. 2013;8(9):e74492.
   PubMed Web of Science ®Google Scholar
• NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–795.
   PubMed Web of Science ®Google Scholar
• Kimura T, Koike Y, Aikawa K, et al. Short-term impact of androgen deprivation therapy on bone strength in castration-sensitive prostate cancer. Int J Urol. 2019;26(10):980–984.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Turner CH, Peacock M, et al. Geometric structure of the femoral neck measured using dual-energy x-ray absorptiometry. J Bone Miner Res. 2009;9(7):1053–1064.
   Google Scholar
• Faulkner KG, Wacker WK, Barden HS, et al. Femur strength index predicts hip fracture independent of bone density and hip axis length. Osteoporos Int. 2006;17(4):593–599.
   PubMed Web of Science ®Google Scholar
• Zhang H, Hu YQ, Zhang ZL. Age trends for hip geometry in Chinese men and women and the association with femoral neck fracture. Osteoporos Int. 2011;22(9):2513–2522.
   PubMed Web of Science ®Google Scholar
• Szulc P, Duboeuf F, Schott AM, et al. Structural determinants of hip fracture in elderly women: re-analysis of the data from the EPIDOS study. Osteoporos Int. 2006;17(2):231–236.
   PubMed Web of Science ®Google Scholar
• Takakuwa M, Iwamoto J, Konishi M, et al. Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study. J Bone Miner Metab. 2011;29(1):88–95.
   PubMed Web of Science ®Google Scholar
• Takakuwa M, Iwamoto J, Itabashi K. Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA. Clin Drug Investig. 2012;32(2):121–129.
   PubMed Web of Science ®Google Scholar
• Lees MJ, Beggs CB, Barlow MJ, et al. Bone density and cross-sectional geometry of the proximal femur are bilaterally elevated in elite cricket fast bowlers. J Clin Densitom. 2018;21(3):399–405.
   PubMed Web of Science ®Google Scholar
• Deere K, Sayers A, Rittweger J, et al. Habitual levels of high, but not moderate or low, impact activity are positively related to hip BMD and geometry: results from a population-based study of adolescents. J Bone Miner Res. 2012;27(9):1887–1895.
   PubMed Web of Science ®Google Scholar
• Kato S, Kawase M, Kato D, et al. Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy. J Bone Miner Metab. 2019;37(1):72–80.
   PubMed Web of Science ®Google Scholar
• Wang W, Yuasa T, Tsuchiya N, et al. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer. 2008;15(4):943–952.
   PubMed Web of Science ®Google Scholar
• WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163.
   PubMed Web of Science ®Google Scholar
• Examination Committee of Criteria for ‘Obesity Disease’ in Japan; Japan Society for the Study of Obesity. New criteria for ‘obesity disease’ in Japan. Circ J. 2002;66:987–992.
   PubMed Web of Science ®Google Scholar
• Schwaiger BJ, Kopperdahl DL, Nardo L, et al. Vertebral and femoral bone mineral density and bone strength in prostate cancer patients assessed in phantomless PET/CT examinations. Bone. 2017;101:62–69.
   PubMed Web of Science ®Google Scholar
• Beck TJ, Oreskovic TL, Stone KL, et al. Structural adaptation to changing skeletal load in the progression toward hip fragility: the study of osteoporotic fractures. J Bone Miner Res. 2001;16(6):1108–1119.
   PubMed Web of Science ®Google Scholar
• Iki M, DongMei N, Tamaki J, et al. Age-specific reference values of hip geometric indices from a representative sample of the Japanese female population: Japanese Population-based Osteoporosis (JPOS) Study. Osteoporos Int. 2011;22(6):1987–1996.
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang Y, Cheng X, et al. The effect of age on the changes in bone mineral density and osteoporosis detection rates in Han Chinese men over the age of 50. Aging Male. 2014;17(3):166–173.
   PubMed Web of Science ®Google Scholar
• Shahtaheri SM. The microanatomy of trabecular bone in young normal and osteoporotic elderly males. Aging Male. 2007;10(2):71–75.
   PubMed Web of Science ®Google Scholar
• Choong K, Basaria S. Emerging cardiometabolic complications of androgen deprivation therapy. Aging Male. 2010;13(1):1–9.
   PubMed Web of Science ®Google Scholar
• Duarte MF, Luis C, Baylina P, et al. Clinical and metabolic implications of obesity in prostate cancer: is testosterone a missing link? Aging Male. 2019;22(4):228–240.
   PubMed Web of Science ®Google Scholar
• Di Sebastiano KM, Pinthus JH, Duivenvoorden WC, et al. Elevated C-peptides, abdominal obesity, and abnormal adipokine profile are associated with higher Gleason scores in prostate cancer. Prostate. 2017;77(2):211–221.
   PubMed Web of Science ®Google Scholar
• Lavalette C, Tretarre B, Rebillard X, et al. Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study. Oncotarget. 2018;9(77):34485–34494.
   PubMedGoogle Scholar
• Sogaard AJ, Holvik K, Omsland TK, et al. Abdominal obesity increases the risk of hip fracture. A population-based study of 43,000 women and men aged 60-79 years followed for 8 years. Cohort of Norway. J Intern Med. 2015;277:306–317.
   PubMed Web of Science ®Google Scholar
• Meyer HE, Willett WC, Flint AJ, et al. Abdominal obesity and hip fracture: results from the nurses’ health study and the health professionals follow-up study. Osteoporos Int. 2016;27(6):2127–2136.
   PubMed Web of Science ®Google Scholar
• Mitsuzuka K, Kyan A, Sato T, et al. Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer. Prostate Cancer Prostatic Dis. 2016;19(1):57–62.
   PubMed Web of Science ®Google Scholar
• Boxer RS, Kenny AM, Dowsett R, et al. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male. 2005;8(3–4):207–212.
   PubMedGoogle Scholar
• Bredella MA, Lin E, Gerweck AV, et al. Determinants of bone microarchitecture and mechanical properties in obese men. J Clin Endocrinol Metab. 2012;97(11):4115–4122.
   PubMed Web of Science ®Google Scholar
• Teoh JY, Chiu PK, Chan SY, et al. Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer. Aging Male. 2015;18(3):180–185.
   PubMed Web of Science ®Google Scholar